Orchid Pharma Limited (Orchid Pharma) announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications. Chennai-based Orchid Pharma has partnered with Cipla Limited (Cipla) to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India.
Orchid Pharma, a Chennai-based leading pharmaceutical company catering across the pharmaceutical value chain (discovery to delivery) with expertise in R&D and marketing, has announced the appointment of Rajnish Rohatgi as chief executive officer. He will be responsible for setting up a new division focused on promoting the rational use of anti-infectives, to favourably impact a key aspect of Indian public health.
Orchid Pharma, based in Chennai, has received Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity Active Pharmaceutical Ingredient (API), Enmetazobactam.
Orchid Pharma has secured approval from the Drugs Controller General of India (DCGI) to manufacture and market its new chemical entity (NCE), the active pharmaceutical ingredient (API) Enmetazobactam.
Chennai-based Orchid Pharma has received Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity active pharmaceutical ingredient (API), enmetazobactam.
Orchid Pharma Ltd has posted a decline of 44 per cent in net profit at Rs. 32.96 crore during the fourth quarter of the fiscal year 2023-24, as compared to Rs. 59.14 crore registered in the corresponding period of previous fiscal year on a consolidated basis.
Expansion plans include a new facility, Enmetazobactam launch, and mergers for sustainable growth and reduced import reliance. Orchid Pharma, which is seeing a turnaround under its new promoter Dhanuka Group, aspires to be a fully integrated powerhouse of cephalosporin antibiotics, the company's top executive said
Orchid Pharma, a subsidiary of India’s Dhanuka Labs, has gained a sublicense to manufacture the antibiotic cefiderocol as part of an effort to expand access worldwide.
Orchid Pharma, the Chennai-based drug maker on Tuesday said it has entered into a technology transfer agreement with a leading multinational biotechnology company for its fermentation based ‘7ACA project’ under the production linked incentive (PLI) scheme. nnnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/orchid-pharma-enter-tech-transfer-pact-to-make-key-cephalosporin-intermediate/articleshow/101676645.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Orchid Pharma Limited has posted net profit of Rs. 59.13 crores for the period ended March 31, 2023 as against net profit of Rs. 7.58 crores for the period ended December 31, 2022. The company posted net loss of Rs. 6.58 crores for the period ended March 31, 2022.